創業慧康(300451.SZ):公司在今年成功收購了一家西部地區的區域型公司
格隆匯9月21日丨創業慧康(300451.SZ)近期在接待機構投資者調研時表示,當前行業內的廠商數量眾多且地域性明顯,導致市場份額分散。近年來,隨着行業規模的擴大和行業需求的不斷深化,醫療信息化市場的頭部公司逐漸提高了其市場份額,並逐漸擠佔了地域性和單一細分領域的廠商,迫使這些區域性廠商不得不尋求與頭部公司進行合作。公司在今年也成功收購了一家西部地區的區域型公司,增強了地區優勢。在未來的發展中,我司將在致力實現內部增長的同時,積極利用資本市場這一平台,繼續審慎地推進外延式發展戰略,以進一步鞏固和加強公司的競爭優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.